Related Experiment Videos
Antibodies to simian virus 5 in patients with multiple sclerosis and other neurological disorders
B Brankin1, G B Wisdom, I V Allen
1Department of Biochemistry, Queen's University, Belfast, Northern Ireland, U.K.
Abstract:
Antibodies to the paramyxovirus simian virus 5 were measured in cerebrospinal fluid samples using an enzyme-linked immunosorbent assay. Six of the 13 clinically definite MS patients had elevated levels of antibodies compared with other neurological disease and orthopaedic controls. None of the samples from MS patients classed as probable or possible had increased amounts of SV5 antibodies. Simian virus 5 antibodies and measles antibodies showed a weak correlation and it is suggested that the elevated levels of the former are a manifestation of the increased antiviral response found in some MS patients.
Insights
Elevated antibodies to simian virus 5 (SV5) were found in some definite multiple sclerosis (MS) patients. This suggests a potential link between SV5 infection and the heightened antiviral responses observed in MS.
Area of Science:
- Neuroimmunology
- Virology
- Infectious Diseases
Background:
- Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
- The role of viral infections in the etiology or pathogenesis of MS remains an area of active investigation.
- Paramyxoviruses, such as simian virus 5 (SV5), have been explored for potential associations with neurological disorders.
Purpose of the Study:
- To investigate the presence and significance of antibodies to simian virus 5 (SV5) in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS).
- To determine if elevated SV5 antibody levels correlate with MS diagnosis or disease status.
- To explore the relationship between SV5 antibodies and other antiviral responses in MS patients.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was employed to quantify SV5-specific antibodies in CSF samples.
- CSF samples were analyzed from patients with clinically definite, probable, and possible MS.
- Control groups included patients with other neurological diseases and orthopaedic conditions.
Main Results:
- Elevated levels of SV5 antibodies were detected in the CSF of 6 out of 13 patients with clinically definite MS.
- No increased SV5 antibody levels were observed in patients classified as probable or possible MS.
- A weak correlation was found between SV5 antibodies and measles antibodies, suggesting a broader antiviral response.
Conclusions:
- The findings suggest that elevated SV5 antibodies in definite MS patients may reflect an increased general antiviral immune response rather than a specific etiological role of SV5.
- Further research is warranted to elucidate the complex interplay between viral infections and the immune system in the context of multiple sclerosis.
- The study highlights the potential utility of measuring specific antibody levels in CSF for understanding immune dysregulation in MS.